Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roos

Showing results (401-410 of 608) with videos related to

Pageof 61
Sort By:
Histochemistry and Cell Biology|February 9, 2008
Islet beta-cell area and hormone expression are unaltered in Huntington's diseaseKarl Bacos, Maria Björkqvist, Asa Petersén, et al.
Neurology|April 26, 2013
8OHdG is not a biomarker for Huntington disease state or progressionBeth Borowsky, John Warner, Blair R Leavitt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 25, 2014
Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's diseaseJ A Bouwens, A A M Hubers, E van Duijn, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 28, 2018
Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancySebastian K Frees, Mohammed M Kamal, Sebastian Nestler, et al.
Urology|June 6, 2016
Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched AnalysisSebastian Frees, Mohammed M Kamal, Lisa Knoechlein, et al.
Pharmacogenetics|April 3, 2002
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control studyIgor Schillevoort, Anthonius de Boer, Jan van der Weide, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 17, 2004
Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-upJeroen P P van Vugt, Karlijne K E Piet, Liesbeth J Vink, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patientsE Boven, H J Haisma, H Bril, et al.
Investigative Radiology|March 1, 1994
Attenuation of monochromatic X-rays by normal and abnormal breast tissuesF E Carroll, J W Waters, W W Andrews, et al.
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
Pageof 61

Showing results (401-410 of 608) with videos related to

Sort By:
Pageof 61
Histochemistry and Cell Biology|February 9, 2008
Islet beta-cell area and hormone expression are unaltered in Huntington's diseaseKarl Bacos, Maria Björkqvist, Asa Petersén, et al.
Neurology|April 26, 2013
8OHdG is not a biomarker for Huntington disease state or progressionBeth Borowsky, John Warner, Blair R Leavitt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 25, 2014
Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's diseaseJ A Bouwens, A A M Hubers, E van Duijn, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 28, 2018
Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancySebastian K Frees, Mohammed M Kamal, Sebastian Nestler, et al.
Urology|June 6, 2016
Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched AnalysisSebastian Frees, Mohammed M Kamal, Lisa Knoechlein, et al.
Pharmacogenetics|April 3, 2002
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control studyIgor Schillevoort, Anthonius de Boer, Jan van der Weide, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 17, 2004
Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-upJeroen P P van Vugt, Karlijne K E Piet, Liesbeth J Vink, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patientsE Boven, H J Haisma, H Bril, et al.
Investigative Radiology|March 1, 1994
Attenuation of monochromatic X-rays by normal and abnormal breast tissuesF E Carroll, J W Waters, W W Andrews, et al.
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
Pageof 61